Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

16.07 -0.60 (-3.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,855,067
Open 16.56
Bid (Size) 15.82 (1)
Ask (Size) 16.79 (2)
Prev. Close 16.67
Today's Range 15.81 - 16.79
52wk Range 15.81 - 41.06
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
From Guardant Health, Inc.
Via Business Wire
Analyst Expectations For Guardant Health's Future
Via Benzinga

Performance

YTD
-39.38%
-39.38%
1 Month
-10.37%
-10.37%
3 Month
-30.76%
-30.76%
6 Month
-37.30%
-37.30%
1 Year
-34.67%
-34.67%

More News

Read More
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
From Guardant Health, Inc.
Via Business Wire
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
Via Investor's Business Daily
Better Than ChatGPT? New Super AI Bot Says Buy These 3 Stocks.
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
4 Analysts Have This To Say About Guardant Health
Via Benzinga
Guardant Health: Q4 Earnings Insights
Via Benzinga
Decoding 4 Analyst Evaluations For Guardant Health
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Insiders Buying Advance Auto Parts And 2 Other Stocks
Via Benzinga
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
From Guardant Health, Inc.
Via Business Wire
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
From Guardant Health, Inc.
Via Business Wire
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Via Benzinga
Exposures Product Safety
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Guardant Health, Inc.
Via Business Wire
3 Stocks to Buy for the Age of Personalized Medicine
Via InvestorPlace
Guardant Health to present data at ASCO GI supporting use of liquid biopsy to predict colon cancer recurrence
From Guardant Health, Inc.
Via Business Wire
Bull of the Day - NeoGenomics
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024
Via InvestorPlace
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
From Guardant Health, Inc.
Via Business Wire
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Via The Motley Fool
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
From Guardant Health, Inc.
Via Business Wire
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
From Guardant Health, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.